Literature DB >> 2337902

Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.

L M Weiskirch1, E Barker, M B Mokyr.   

Abstract

We have previously shown that spleen cells from BALB/c mice that are in the process of eradicating a large MOPC-315 tumor following low-dose (2.5 mg/kg) melphalan (L-phenylalanine mustard) therapy are effective in preventing tumor progression upon adoptive transfer into BALB/c mice bearing a barely palpable tumor that had been treated with a subcurative dose of melphalan [Mokyr et al. (1989) Cancer Res 49:4597]. Here we show that such spleen cells in conjunction with a subcurative dose of drug (adoptive chemoimmunotherapy, ACIT) can cause the complete regression of a large (15-20 mm) s.c. MOPC-315 tumor in a large percentage of T-cell-deficient (athymic nude) tumor-bearing mice. Spleen cells that were effective in ACIT of athymic nude mice displayed in vitro a substantial direct lytic activity against MOPC-315 tumor cells, and the lytic activity was greatly enhanced when the spleen cells were cultured for 5 days with or without mitomycin-C-treated MOPC-315 stimulator tumor cells. The cells responsible for the therapeutic effectiveness of the spleen cells in ACIT of athymic nude mice, as well as the cells responsible for the direct in vitro anti-MOPC-315 lytic activity of the spleen cells, were of the Lyt 2 and not the L3T4 phenotype. Most of the athymic nude mice that completely eradicated a large MOPC-315 tumor as a consequence of ACIT were capable of rejecting a challenge with 30-100 times the minimal lethal tumor dose for 100% of normal BALB/c mice administered more than 1 month after the ACIT. The ability of these athymic nude mice to resist the tumor challenge was associated with the presence of a greatly elevated percentage of cells expressing T cell surface markers in their spleens. Thus, it is conceivable that splenic Lyt 2+T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor mediate their therapeutic effectiveness in ACIT of athymic nude mice bearing a large MOPC-315 tumor, at least in part, through direct cytotoxicity for MOPC-315 tumor cells. In addition, eradication of a large MOPC-315 tumor through cooperation between antitumor immunity and melphalan toxicity endues the athymic nude mice with an elevated percentage of T cells in their secondary lymphoid organs, and these T cells are probably responsible for the long-lasting protective antitumor immunity exhibited by these mice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2337902     DOI: 10.1007/bf01744726

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  30 in total

Review 1.  Down-regulation of the antitumor immune response.

Authors:  R J North
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

2.  Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

Authors:  M Röllinghoff; B T Rouse; N L Warner
Journal:  J Natl Cancer Inst       Date:  1973-01       Impact factor: 13.506

3.  Modification of tumor regression by immunologic means.

Authors:  E Mihich
Journal:  Cancer Res       Date:  1969-12       Impact factor: 12.701

4.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.

Authors:  M B Mokyr; E Barker; L M Weiskirch; B Y Takesue; J M Pyle
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

6.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Impaired clonal expansion in athymic nude CD8+CD4- T cells.

Authors:  J T Kung
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

8.  Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.

Authors:  M B Mokyr; E Barker
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice.

Authors:  M Glaser
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

10.  Specificity of cytotoxic T cells from athymic mice.

Authors:  T Hünig; M J Bevan
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

View more
  3 in total

1.  Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

Authors:  L M Weiskirch; Y Bar-Dagan; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

2.  Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.

Authors:  M Laude; K L Russo; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

3.  Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.

Authors:  L M Weiskirch; B A Baumgartel; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.